Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 467

1.

Rheumatic diseases: the effects of inflammation on bone.

Walsh NC, Crotti TN, Goldring SR, Gravallese EM.

Immunol Rev. 2005 Dec;208:228-51. Review.

PMID:
16313352
2.
3.

Osteoclast precursors, RANKL/RANK, and immunology.

Xing L, Schwarz EM, Boyce BF.

Immunol Rev. 2005 Dec;208:19-29. Review.

PMID:
16313338
4.

Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.

Anandarajah AP, Schwarz EM.

J Cell Biochem. 2006 Feb 1;97(2):226-32. Review.

PMID:
16240334
5.

Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.

Cheng X, Kinosaki M, Takami M, Choi Y, Zhang H, Murali R.

J Biol Chem. 2004 Feb 27;279(9):8269-77. Epub 2003 Dec 15.

6.

Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.

Tanaka S, Nakamura K, Takahasi N, Suda T.

Immunol Rev. 2005 Dec;208:30-49. Review.

PMID:
16313339
7.

Bone destruction in arthritis.

Gravallese EM.

Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii84-6. Review.

8.
9.

RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.

Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM.

Rheumatology (Oxford). 2006 Sep;45(9):1068-76. Epub 2006 Feb 20.

PMID:
16490750
10.

Osteoclasts, pro-inflammatory cytokines, RANK-L and bone remodeling in rheumatoid arthritis.

Kaplan C, Finnegan A.

Front Biosci. 2003 May 1;8:d1018-29.

PMID:
12700082
11.
12.

Bone loss in inflammatory arthritis: mechanisms and treatment strategies.

Walsh NC, Gravallese EM.

Curr Opin Rheumatol. 2004 Jul;16(4):419-27. Review.

PMID:
15201606
13.

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM.

Nature. 1999 Nov 18;402(6759):304-9.

PMID:
10580503
14.

RANKL-RANK signaling in osteoclastogenesis and bone disease.

Wada T, Nakashima T, Hiroshi N, Penninger JM.

Trends Mol Med. 2006 Jan;12(1):17-25. Epub 2005 Dec 13. Review.

PMID:
16356770
15.
16.

[Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].

Ferrer Cañabate J, Tovar I, Martínez P.

An Med Interna. 2002 Aug;19(8):385-88. Review. Spanish. No abstract available.

PMID:
12244784
17.

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.

Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D.

Cytokine Growth Factor Rev. 2004 Dec;15(6):457-75. Review.

PMID:
15561602
18.

The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.

Yeung RS.

J Rheumatol. 2004 May;31(5):844-6. Review. No abstract available.

19.

LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.

Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, Athanasou NA, Sabokbar A.

Arthritis Rheum. 2006 May;54(5):1451-62.

20.

Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice.

Maruyama K, Takada Y, Ray N, Kishimoto Y, Penninger JM, Yasuda H, Matsuo K.

J Immunol. 2006 Sep 15;177(6):3799-805.

Supplemental Content

Support Center